BIOCOM, Inc. is a life science association. The company focuses on initiatives that influence the region’s life science community in the development and delivery of products, as well as on capital formation, public policy, workforce development, group purchasing, and member services, such as networking events. It represents life sciences communities in Southern California. The company was founded in 1991 and is based in San Diego, California with an additional office in Los Angeles, California.
4510 Executive Drive
San Diego, CA 92121
Founded in 1991
Biocom Expands Team in Los Angeles
Sep 1 16
Biocom announced that its recently-opened Los Angeles office is now fully staffed and operational, advancing on its mission to accelerate life science success in specific and meaningful ways for its members. The new hires bring the Los Angeles office staff total to five. In San Diego, the addition of six new employees represents organic growth at the headquarters office. Biocom's full-time staff across its four offices now stands at 40.
Biocom Appoints Directors to its Board
Aug 30 16
Biocom announced the appointment of two new directors to its board. David Weitz, Head of Takeda California and Global Research Externalization for parent company Takeda Pharmaceutical Company, Limited, and Wolfgang Glaesner, Ph.D., Chief Scientific Officer at Eli Lilly and Company, were appointed to the board, bringing total board membership to 60. David Weitz, J.D., is the Head of Takeda California and Global Research Externalization for parent company Takeda Pharmaceutical Company Ltd. As the leader of Takeda California, David works to maintain the San Diego site's agile, collaborative and entrepreneurial approach to drug discovery research. As Head of Global Research Externalization, David uses his 24 years of experience in research, business, legal, and intellectual property, as well as a proven track record of alliance formation, to increase the agility of Takeda's Research Division in securing external partnerships and collaborations as a key source of innovation. David began his career as a patent attorney and in 2000 became the first patent attorney to be elected to partnership at Wilson Sonsini Goodrich & Rosati. David joined Syrrx as its General Counsel in 2002. Following Syrrx's acquisition by Takeda in 2005, David has been heavily involved with the integration of Syrrx, Takeda San Francisco and Envoy and numerous business development efforts for Takeda both locally and for the parent company. Dr. Wolfgang Glaesner is Chief Scientific Officer at Lilly in San Diego. Dr. Glaesner first joined Lilly in Indianapolis, working as a protein biochemist in the protein optimization team. In 2009, Dr. Glaesner moved to California to head Lilly's research group. His research interests include the biology of glucagon-like peptide -1, time extension strategies of proteins and peptides, as well as alternative protein scaffolds and their applications in treatment of human disease.
Biocom Announces Board Appointments
Jun 7 16
Biocom announced the appointment of 13 new directors to its board, including the appointment of Charles Dadswell, senior vice president and general counsel for Illumina, and Rich Pascoe, chief executive officer of Apricus Biosciences, to the executive committee of Biocom's board. In addition, Biocom announced that Magda Marquet, Ph.D., co-founder of Ajinomoto Althea and AltheaDx, and Brent D. Jacobs, executive director in the global life sciences practice group at Cushman & Wakefield, were named as life directors, a prestigious and special class of director. At Illumina, Mr. Dadswell is SVP, general counsel & secretary. He has worldwide responsibility for all legal, government affairs, and intellectual property matters. Before joining Illumina, Mr. Dadswell was vice president, general counsel for North and Latin America and corporate director of global intellectual property at bioMerieux. Mr. Pascoe joined Apricus as CEO in March of 2013 following the merger of Somaxon Pharmaceuticals, where he had served as chief executive officer since August 2008, with Pernix. The additional new members of the board are: Bruno Buisson, Ph.D., founder, general manager and chief scientist, Neuroservice; Peter Callstrom, president and CEO, San Diego Workforce Partnership; Sunita "Sunny" Cooke, Ph.D., superintendent/president, Mira Costa College; Carol Cox, executive vice president, strategy, corporate development and external affairs, NuVasive; J. David Enloe, Jr., president and CEO, Althea; James Mackay, Ph.D., president and chief operating officer, Ardea Biosciences/AstraZeneca; Steven R. Pacelli, executive vice president, strategy and corporate development, Dexcom; Dean Samsvick, partner in charge, Southern California life science practice, KPMG; Stephen Welter, Ph.D., vice president for research and dean of graduate affairs, San Diego State University; Kenneth Weixel, managing partner, San Diego, Deloitte & Touche LLP; Matthew Williams, vice president, state government affairs, AbbVie.